---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-24-000013"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:41:30.629942+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Artivion Q4 revenue $93.7M (+18% YoY); guides 2024 rev $382-396M

## Summary
- Q4 revenue $93.7M (+18% GAAP, +15% constant currency); full year $354.0M (+13%).
- Q4 non-GAAP net income $4.6M ($0.11 EPS); adjusted EBITDA $15.3M (+40% YoY).
- Full year net loss ($30.7M); non-GAAP net income $8.4M ($0.20 EPS); free cash flow $11.4M.
- 2024 guidance: revenue $382-396M (+8-12%), adjusted EBITDA $68-72M (+26-34%).
- AMDS PERSEVERE trial met endpoints: 72% mortality reduction, 52% fewer MAEs; FDA PMA expected H2 2025.

## SEC filing metadata
- accession: 0000784199-24-000013
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/0000784199-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/aort-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-24-000013
- JSON: https://secwatch.observer/filing/0000784199-24-000013.json
- Plain text: https://secwatch.observer/filing/0000784199-24-000013.txt

## Key facts
- Earnings Releases
  ARTIVION, INC. reported fourth quarter ended December 31, 2023 results: revenue $93.7 million, net income ($4.0) million, or ($0.10) per fully diluted common share, EPS ($0.10) per fully diluted common share.
  - Period: fourth quarter ended December 31, 2023
  - Revenue: $93.7 million
  - Net income: ($4.0) million, or ($0.10) per fully diluted common share
  - EPS: ($0.10) per fully diluted common share
  - Result: reported results
  source text: Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2023 Financial Results Fourth Quarter and Recent Business Highlights: • Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis • Achieved
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/0000784199-24-000013-index.htm
- Earnings Releases
  ARTIVION, INC. reported full year 2024 results: revenue $382 to $396 million. Guidance initiated.
  - Period: full year 2024
  - Revenue: $382 to $396 million
  - Guidance: initiated
  - Result: guidance update
  source text: The Company expects revenues for the full year 2024 to be in the range of $382 to $396 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/0000784199-24-000013-index.htm
- Earnings Releases
  ARTIVION, INC. reported full year ended December 31, 2023 results: revenue $354.0 million, net income ($30.7) million, or ($0.75) per fully diluted common share, EPS ($0.75) per fully diluted common share.
  - Period: full year ended December 31, 2023
  - Revenue: $354.0 million
  - Net income: ($30.7) million, or ($0.75) per fully diluted common share
  - EPS: ($0.75) per fully diluted common share
  - Result: reported results
  source text: fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis • Achieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency basis • Net loss was ($4.0)
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/0000784199-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.